Hubalek MM - Search Results

1

Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer.

Widschwendter A, Müller HM, Hubalek MM, Wiedemair A, Fiegl H, Goebel G, Mueller-Holzner E, Marth C, Widschwendter M. Widschwendter A, et al. Among authors: hubalek mm. Gynecol Oncol. 2004 May;93(2):407-16. doi: 10.1016/j.ygyno.2004.01.036. Gynecol Oncol. 2004. PMID: 15099954

2

hCDC4 gene mutations in endometrial cancer.

Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M, Reed SI. Spruck CH, et al. Cancer Res. 2002 Aug 15;62(16):4535-9. Cancer Res. 2002. PMID: 12183400

3

MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status.

Müller HM, Fiegl H, Goebel G, Hubalek MM, Widschwendter A, Müller-Holzner E, Marth C, Widschwendter M. Müller HM, et al. Among authors: hubalek mm. Br J Cancer. 2003 Nov 17;89(10):1934-9. doi: 10.1038/sj.bjc.6601392. Br J Cancer. 2003. PMID: 14612906 Free PMC article.

4

Cyclin E dysregulation and chromosomal instability in endometrial cancer.

Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl HM, Müller HM, Goebel G, Mueller-Holzner E, Marth C, Spruck CH, Reed SI, Widschwendter M. Hubalek MM, et al. Oncogene. 2004 May 20;23(23):4187-92. doi: 10.1038/sj.onc.1207560. Oncogene. 2004. PMID: 15048079

5

Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer.

Hubalek M, Ramoni A, Mueller-Holzner E, Marth C. Hubalek M, et al. Gynecol Oncol. 2004 Oct;95(1):264-6. doi: 10.1016/j.ygyno.2004.06.039. Gynecol Oncol. 2004. PMID: 15385144

6

Chemotherapeutic treatment of a pregnant patient with ovarian dysgerminoma.

Hubalek M, Smekal-Schindelwig C, Zeimet AG, Sergi C, Brezinka C, Mueller-Holzner E, Marth C. Hubalek M, et al. Arch Gynecol Obstet. 2007 Aug;276(2):179-83. doi: 10.1007/s00404-007-0328-2. Arch Gynecol Obstet. 2007. PMID: 17342499

7

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Gnant M, et al. Lancet Oncol. 2008 Sep;9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19. Lancet Oncol. 2008. PMID: 18718815 Clinical Trial.

8

E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer.

Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Illmensee K, Altevogt P, Zeimet AG. Reimer D, et al. Cancer Res. 2010 Jun 1;70(11):4613-23. doi: 10.1158/0008-5472.CAN-09-3551. Epub 2010 May 11. Cancer Res. 2010. PMID: 20460525

9

Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.

Hubalek M, Brantner C, Marth C. Hubalek M, et al. Wien Med Wochenschr. 2010 Apr;160(7-8):167-73. doi: 10.1007/s10354-010-0771-8. Wien Med Wochenschr. 2010. PMID: 20473727

10

Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.

Hubalek M, Brunner C, Matthä K, Marth C. Hubalek M, et al. Wien Med Wochenschr. 2010 Nov;160(19-20):506-12. doi: 10.1007/s10354-010-0838-6. Epub 2010 Oct 26. Wien Med Wochenschr. 2010. PMID: 20972709 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters